Statement Of Cash Flows [Abstract]

Alligator Bioscience - Filing #690835

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
193 403 SEK
193 403 SEK
- SEK
- SEK
141 736 SEK
141 736 SEK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for depreciation and amortisation expense
11 767 SEK
11 144 SEK
Adjustments for share-based payments
99,000 SEK
4,000 SEK
Other adjustments for non-cash items
19,000 SEK
65,000 SEK
Interest paid, classified as operating activities
646,000 SEK
235,000 SEK
Cash flows from (used in) operating activities
172 607 SEK
127 033 SEK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
440,000 SEK
45,000 SEK
Cash flows from (used in) investing activities
440,000 SEK
45,000 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
380,000 SEK
342 665 SEK
Payments to acquire or redeem entity's shares
380,000 SEK
- SEK
Repayments of borrowings, classified as financing activities
104,000 SEK
301,000 SEK
Payments of lease liabilities, classified as financing activities
7 806 SEK
6 672 SEK
Cash flows from (used in) financing activities
7 827 SEK
301 795 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
32,000 SEK
60,000 SEK
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
180 875 SEK
174 717 SEK
Cash and cash equivalents
97 305 SEK
278 148 SEK
103 342 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.